Manufacturer
50 recalls in our database name Clinical Specialties Compounding Pharmacy as the manufacturing or recalling firm.
Of the 50 recalls from Clinical Specialties Compounding Pharmacy we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 47 (94%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Clinical Specialties Compounding Pharmacy is recalling Vancomycin 50 mg/ml due to FDA inspection findings regarding quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling 12ml vials of Test cyp 50 mg/ml due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Cyclosporine 2% ophthalmic due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test cyp 25 mg-Estadiol valerate 15 mg/mL due to lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 50 mg-estradiol cyp 2 mg/ml due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling HCG 2000 units/ml syringes because FDA inspection findings raised concerns about quality control and assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling ophthalmic dilation gel due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Tetracaine 0.25% solution due to FDA inspection findings regarding quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling Hydroxyprogesterone 250 mg/ml because FDA inspections raised concerns about quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling Acetylcysteine 20% solution due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 10 mg/ml vials due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling 11ml vials of Test cyp 75 mg-estradiol cyp 5 mg/ml due to lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling HCG 1000 units/ml syringes due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling a specific lot of Test cyp 25 mg-Estradiol cyp 5 mg/ml injection due to lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Itraconazole 1% eye ointment because FDA inspections raised concerns about quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling specific lots of Test Cyp 50 mg-estradiol cyp 2 mg/ml due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test cyp 35 mg/ml due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling specific lots of Mitomycin (modified) 0.02% solution because FDA inspection findings raised concerns about quality control processes and assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 50 mg-estradiol cyp 7 mg/ml due to lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling specific lots of Cyclosporine 1% ophthalmic drops due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Estradiol Valerate 20 mg/ml injections due to FDA inspection findings regarding quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling Medroxyprogesterone 150 mg/ml injections because FDA inspections raised concerns about quality control and sterility assurance.
Clinical Specialties Compounding Pharmacy is recalling cataract drops due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 25 mg-e(2) blend 12 mg/ml due to FDA inspection findings regarding quality control and lack of assurance of sterility.
Clinical Specialties Compounding Pharmacy is recalling Diazepam 5 mg/ml due to FDA inspection findings regarding quality control and lack of sterility assurance.